CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy.
CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy.
复制标题
DOI：
10.1016/j.jvir.2011.01.451
复制
发表时间：
2011-06
影响因子：
2.9
通讯作者：
Kemeny, Nancy E.
中科院分区：
文献类型：
--
作者：
Sofocleous, Constantinos T.;Petre, Elena N.;Gonen, Mithat;Brown, Karen T.;Solomon, Stephen B.;Covey, Anne M.;Alago, William;Brody, Lynn A.;Thornton, Raymond H.;D'Angelica, Michael;Fong, Yuman;Kemeny, Nancy E.
目的评价经皮射频消融治疗肝切除术后复发的结直肠癌肝转移瘤的临床疗效。从2002年12月到2008年12月，我们消融了56例肝切除术后发生的71个CLM。我们回顾了医疗记录和影像，以确定：技术效果/完全消融(消融后4-6周CT上覆盖整个肿瘤的消融缺陷)、并发症和消融部位的局部肿瘤进展。采用Kaplan-Meier方法计算局部肿瘤无进展生存率和总生存率。改良的临床风险评分(CRS)包括原发灶的结节状态、从原发灶到肝转移的时间间隔、肿瘤个数和最大肿瘤的大小，与总生存率和局部肿瘤进展相关。肿瘤大小0.5~5.7 cm。完全消融67/71例(94%)。并发症有：肝脓肿、胸腔积液。中位总生存期为31个月。1、2、3年总生存率分别为91%、66%、41%。CRS是影响总生存率(两年内CRS0-2组为74%，CRS3-4组为42%，P=0.03)和局部肿瘤无进展生存率(CRS0-2组为66%，CRS3-4组为22%)的独立因素。CT引导下射频消融可用于治疗肝切除术后复发的CLM。较低的CRS与较好的临床结果相关。
To evaluate the clinical outcomes of percutaneous radiofrequency (RF) ablation of colorectal cancer liver metastases (CLM) recurring after hepatectomy. From December 2002 to December 2008 we ablated 71 CLM developing after hepatectomy in 56 patients. We reviewed medical records and imaging to determine: technique effectiveness/complete ablation (ablation defect covering the entire tumor on 4–6 week post-ablation CT), complications and local tumor progression at the site of ablation. Local tumor progression-free and overall survivals were calculated using Kaplan-Meier methodology. A modified clinical risk score (CRS) including nodal status of the primary, time interval from primary to liver metastases, number of tumors and size of the largest tumor was correlated to overall survival and local tumor progression. Tumor size ranged between 0.5 and 5.7 cm. Complete ablation was documented in 67/71 (94%) CLM. Complications were: liver abscess and pleural effusion. Median overall survival was 31 months. One-, 2- and 3-year overall survival rates were 91%, 66% and 41% respectively. CRS was an independent factor for overall survival (74% for CRS 0–2 vs. 42% for CRS 3–4 at 2 years p=0.03) and for local tumor progression-free survival (66% for CRS 0–2 vs 22% for CRS 3–4 at one year after a single ablation p<0.01). CT-guided RF ablation can be used to treat recurrent CLM after hepatectomy. A low CRS is associated with better clinical outcomes.
登录
查看更多内容
影响因子：
5
作者：
Kei, Shiu Kong;Rhim, Hyunchul;Kim, Young-Sun
通讯作者：
Kim, Young-Sun
影响因子：
0.9
作者：
Pulvirenti, A;Garbagnati, F;Mazzaferro, V
通讯作者：
Mazzaferro, V
影响因子：
19.7
作者：
Goldberg, SN;Grassi, CJ;Silverman, SG
通讯作者：
Silverman, SG
影响因子：
9
作者：
Fong, Y;Fortner, J;Blumgart, LH
通讯作者：
Blumgart, LH
影响因子：
19.7
作者：
Rossi, S;Garbagnati, F;Bartolozzi, C
通讯作者：
Bartolozzi, C